التفاصيل البيبلوغرافية
| العنوان: |
Patient reported outcomes (PROs) and user experiences of young children with type 1 diabetes using t:slim X2 insulin pump with control-IQ technology. |
| المؤلفون: |
Hood, Korey K.1 (AUTHOR) kkhood@stanford.edu, Schneider-Utaka, Aika K.1 (AUTHOR), Reed, Zachariah W.2 (AUTHOR), Buckingham, Bruce A.1 (AUTHOR), Cobry, Erin3 (AUTHOR), DeBoer, Mark D.4 (AUTHOR), Ekhlaspour, Laya5 (AUTHOR), Schoelwer, Melissa4 (AUTHOR), Paul Wadwa, R.3 (AUTHOR), Lum, John2 (AUTHOR), Kollman, Craig2 (AUTHOR), Beck, Roy W.2 (AUTHOR), Breton, Marc D.4 (AUTHOR) |
| المصدر: |
Diabetes Research & Clinical Practice. Feb2024, Vol. 208, pN.PAG-N.PAG. 1p. |
| مصطلحات موضوعية: |
*TYPE 1 diabetes, *PATIENT reported outcome measures, *INSULIN pumps, *CONTINUOUS glucose monitoring, *USER experience, *CHILDREN with autism spectrum disorders |
| مستخلص: |
Examine patient-reported outcomes (PROs) after the use of t:slim X2 insulin pump with Control-IQ technology (CIQ) in young children with type 1 diabetes. Children with type 1 diabetes, ages 2 to < 6 years (n = 102), were randomly assigned 2:1 to either CIQ or standard care (SC) with pump or multiple daily injections (MDI) plus continuous glucose monitoring (CGM) for 13 weeks. Both groups were offered to use CIQ for an additional 13 weeks after the randomized control trial's (RCT) completion. Guardians completed PRO questionnaires at baseline, 13-, and 26-weeks examining hypoglycemia concerns, quality of life, parenting stress, and sleep. At 26 weeks, 28 families participated in user-experience interviews. Repeated measures analyses compared PRO scores between systems used. Comparing CIQ vs SC, responses on all 5 PRO surveys favored the CIQ group, showing that CIQ was superior to SC at 26 weeks (p values < 0.05). User-experience interviews indicated significant benefits in optimized glycemic control overall and nighttime control (28 of 28 families endorsed). All but 2/28 families noted substantial reduction in management burden resulting in less mental burden and all but 4 stated that they wanted their children to continue using CIQ. Families utilizing CIQ experienced glycemic benefits coupled with substantial benefits in PROs, documented in surveys and interviews. Families utilizing CIQ had reduced hypoglycemia concerns and parenting stress, and improved quality of life and sleep. These findings demonstrate the benefit of CIQ in young children with type 1 diabetes that goes beyond documented glycemic benefit. [ABSTRACT FROM AUTHOR] |
| قاعدة البيانات: |
Academic Search Index |
